Background
Methods
Study population
Clinical and laboratory measurements
Statistical analysis
Results
Patient demographics and laboratory data
DN (n = 33) | Non-DN (n = 225) |
P-value | |
---|---|---|---|
Male: Female | 16:17 | 111:114 | 0.98 |
Age (years) | 54 (34.50–66) | 49 (31–60) | 0.06 |
Duration of diabetes (years) | 13.92 (5.50–20) | 4.56 (1–8) | <0.001**
|
BMI (kg/m2) | 22.67 (21.85–22.75) | 21.85 (17.75–33.65) | 0.09 |
SBP (mmHg) | 130 (120–140) | 120 (110–125) | <0.001**
|
DBP (mmHg) | 79 (70–80) | 78 (70–80) | 0.81 |
WHR | 0.87 (0.85–0.94) | 0.86 (0.83–0.88) | 0.01*
|
FPG (mmol/L) | 8.24 (5.71–11.47) | 7.73 (6.18–10.70) | 0.48 |
2hPG (mmol/L) | 12.74 + 6.73 | 14.03 + 5.57 | 0.23 |
HbA1c (mmol/mol) | 79 (62–95) | 79 (60–105) | 0.68 |
GA (%) | 27.50 (21.50–31) | 27.50 (23–34) | 0.44 |
CRP (mg/L) | 1.01 (0.66–3.87) | 0.68 (0.27–2.86) | 0.25 |
Uric acid (mg/dL) | 328 (246.50–414.5) | 272 (223–316.50) | <0.001**
|
Cr (mg/dL) | 78 (60–99.50) | 63 (52–74) | 0.01*
|
Fasting C peptide (ng/mL) | 0.19 (0.03–1.13) | 0.29 (0.05–0.80) | 0.56 |
30-min postprandial venous C peptide (ng/mL) | 0.1 (0.03–0.96) | 0.35 (0.05–1.17) | 0.93 |
120-min postprandial venous C peptide (ng/mL) | 0.08 (0.03–1.62) | 0.48 (0.07–1.58) | 0.64 |
Albumin (g/dL) | 41 (37.50–43) | 42.44 (40–45) | <0.001**
|
ALT (U/L) | 16 (11–24.5) | 17 (12–25) | 0.56 |
AST (U/L) | 18 (15–24) | 19 (15–24) | 0.42 |
γ-GT(U/L) | 18 (16–23.50) | 15 (12–22) | 0.73 |
Total Bilirubin (mg/dL) | 0.56 (0.43–0.68) | 0.70 (0.58–0.89) | <0.001**
|
TC (mmol/L) | 4.75 + 1.34 | 4.41 + 0.99 | 0.09 |
TG (mmol/L) | 1.09 (0.87–1.62) | 0.88 (0.70–1.17) | 0.07 |
HDL-C (mmol/L) | 1.28 (0.95–1.66) | 1.27 (1.10–1.60) | 0.59 |
LDL-C (mmol/L) | 2.69 (2.18–3.36) | 2.68 (2.16–3.39) | 0.17 |
Haemoglobin (g/dL) | 126 (109.50–136.5) | 130 (74–171) | 0.04*
|
24 h urinary microalbumin (mg/24 h) | 196.67(49.27–1123.33) | 7.01 (4.89–10.44) | <0.001**
|
Total GFR (mL/min) | 81.75 (60.35–96.03) | 98.95(86.95–107.20) | <0.001**
|
Bilirubin concentrations in serum are independently and negatively associated with 24 h urinary microalbumin
24 h urinary microalbumin (unadjusted) | ||
---|---|---|
r
|
P-value | |
Age | 0.07 | 0.24 |
Duration of diabetes | 0.18 | <0.001**
|
BMI | 0.18 | <0.001**
|
SBP | 0.30 | <0.001**
|
DBP | 0.08 | 0.23 |
WHR | 0.30 | <0.001**
|
FPG | 0.06 | 0.33 |
2hPG | − 0.10 | 0.13 |
HbA1c | 0.02 | 0.72 |
GA | − 0.05 | 0.45 |
CRP | 0.19 | <0.001**
|
Uric acid | 0.23 | <0.001**
|
Cr | 0.20 | <0.001**
|
Fasting C peptide | 0.01 | 0.92 |
30-min postprandial venous C peptide | − 0.02 | 0.80 |
120-min postprandial venous C peptide | − 0.02 | 0.74 |
TC | − 0.01 | 0.98 |
TG | 0.24 | <0.001**
|
HDL-C | − 0.16 | 0.01*
|
LDL-C | − 0.01 | 0.88 |
Albumin | − 0.07 | 0.27 |
Haemoglobin | − 0.03 | 0.65 |
Total bilirubin | − 0.13 | 0.03*
|
Total GFR | − 0.20 | <0.001**
|
Independent variable | Standardised β | t |
P-value |
---|---|---|---|
Cr | 0.45 | 8.34 | <0.001**
|
Total bilirubin | −0.19 | −3.65 | <0.001**
|
SBP | 0.15 | 2.85 | 0.005**
|
Bilirubin concentrations in serum are independently associated with diabetic nephropathy
B | Wald |
P-value | Exp (B) | 95% CI | |
---|---|---|---|---|---|
Duration of diabetes (years) | 0.14 | 17.38 | <0.001**
| 1.15 | 1.07–1.22 |
SBP (mmHg) | 0.05 | 8.93 | <0.001**
| 1.05 | 1.02–1.08 |
Total bilirubin (mg/d) | −3.01 | 5.17 | 0.002**
| 0.05 | 0.01–0.66 |
Bilirubin concentrations in serum are negatively associated with the prevalence of DN in patients with T1DM
Bilirubin quartile | Prevalence (%) | Unadjusted | Adjusted | ||
---|---|---|---|---|---|
OR (95% CI) |
P-value | OR (95% CI) |
P-value | ||
Q1 (n = 64) | 21.90 | 1 (Referent) | |||
Q2 (n = 76) | 17.10 | 0.74 (0.32–1.71) | 0.48 | 0.52 (0.19–1.41) | 0.20 |
Q3 (n = 68) | 7.40 | 0.28 (0.10–0.84) | 0.02* | 0.24 (0.07–0.82) | 0.04* |
Q4 (n = 50) | 2.00 | 0.07 (0.01–0.58) | 0.01* | 0.11 (0.01–0.92) | 0.02* |
P trend for ORs | 0.02* | 0.04* |